4Denton M, Kerr KG. Microbilogical and clinical aspects of infection associated with Stenotrophomonas maltophilia[J]. Clin Microbiol Rev, 1998,11:57-80.
5Pankuch GA, Jancobs MR, Rittenhous SF, et al. Susceptibilities of 123 strains of Stenotrophomonas maltophilia to eight β-lactams (including β-lactam-β-lactamase inhibitor combinations) and ciprofloxacin tested by five methods[J]. Antimicrob Agents Chemother,1994,38:2317-2322.
6National Committee for Clinical Laboratory Stardards.Performance standards for antimicrobial susceptibility testing[S]. Fourteenth informational supplement,2004, M100-S14 ,24 :36-38.
7Zhang L, Li XZ, Poole K. SmeDEF multidrug efflux pump contributes to intrinsic multidrug resistance in Stenotrophomonas maltophilia. Antimicrob[J]. Agents Chemother, 2001,45:3497-3503.
8Garcia-Ga.rrote F, Cercenado E, Bouza E. Evaluation of a new system, VITEK 2, for identification and antimicrobial susceptibility testing of enterococci. J Clin Microbiol, 2000, 35: 2105-2111.
9Joyanes P, del Carmen Conejo M, Martinez-Martinez L, et al. Evaluation of the VITEK 2 system for the identification and susceptibility testing of three species of nonfermenting gramnegative rods frequently isolated from clinical samples. J Clin Microbiol, 2001, 39: 3247-3253.
10Ling TK, Tam PC, Liu ZK, et al. Evaluation of VITEK 2 rapid identification and susceptibility testing system against gramnegative clinical isolates. J Clin Mirobiol, 2001,39: 2964-2966.
